01.07.25 -- Is Your CDMO Using These AI-Driven Solutions In CMC For Oligos And Peptides?

Numerous factors impact a drug safety program, but proper management of three key elements drives success while creating a scalable drug safety model.

A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

A variety of concerns — underscored by supply chain disruptions driven by the COVID-19 pandemic — are pushing companies to redraw global supply chains to resume more domestic manufacturing.

How can you optimize your media for chromatography and improve consistency, yield, and purity through the integration of automation technologies such as advanced slurry preparation systems?

API-sparing development techniques and identifying the appropriate scalable formulation technology to improve drug solubility and enhance oral bioavailability can help increase your chances of success.

Gain insight into the advantages of digitalizing Continued Process Verification (CPV) through the experience of a pharmaceutical company step-by-step.

Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

A leader in the biopharmaceutical industry collaborated with Sartorius to improve the efficiency of their CAR-T cell therapy media preparation. Discover their aliquoting solution.

Learn how a leading CDMO partnered with Körber to quickly deploy a high-speed packaging solution to meet tight production deadlines in the face of a global pandemic.